Abivax SA
PAR:ABVX
Abivax SA
Total Assets
Abivax SA
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abivax SA
PAR:ABVX
|
Total Assets
€120m
|
CAGR 3-Years
19%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Total Assets
€448.2m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
0%
|
CAGR 10-Years
5%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Total Assets
€216.7m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
11%
|
|
|
Inventiva SA
PAR:IVA
|
Total Assets
€179m
|
CAGR 3-Years
18%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Total Assets
$143.2m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
2%
|
|
|
Sensorion SA
PAR:ALSEN
|
Total Assets
€73.3m
|
CAGR 3-Years
14%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
Abivax SA
Glance View
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
See Also
What is Abivax SA's Total Assets?
Total Assets
120m
EUR
Based on the financial report for Jun 30, 2025, Abivax SA's Total Assets amounts to 120m EUR.
What is Abivax SA's Total Assets growth rate?
Total Assets CAGR 5Y
19%
Over the last year, the Total Assets growth was -58%. The average annual Total Assets growth rates for Abivax SA have been 19% over the past three years , 19% over the past five years .
